z-logo
open-access-imgOpen Access
Hemophagocytic Lymphohistiocytosis in Intensive Care Unit
Author(s) -
Thomas Barba,
Delphine Maucort-Boulch,
Jean Iwaz,
Julien Bohé,
J. Ninet,
A. Hot,
JeanChristophe Lega,
Claude Guérin,
Laurent Argaud,
C. Broussolle,
Yvan Jamilloux,
Jean-Christophe Richard,
P. Sève
Publication year - 2015
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000002318
Subject(s) - medicine , intensive care unit , retrospective cohort study , hemophagocytic lymphohistiocytosis , univariate analysis , intensive care , intensive care medicine , organ dysfunction , multivariate analysis , pediatrics , disease , emergency medicine , sepsis
Hemophagocytic lymphohistiocytosis (HLH) is a critical condition that may lead to organ failure and early death. The aim of this retrospective observational study was to describe a cohort of HLH patients admitted to intensive care unit (ICU) and investigate the risk factors of early death. A positive HLH diagnosis was defined by an HScore ≥169. Univariate and multivariate analyses were carried out to investigate hospital and 28-day mortality risk factors. Between January 2002 and July 2014, 71 HLH cases were seen at our institution. The overall 28-day mortality (start at ICU admission) and hospital mortality were 38% and 68%, respectively. The factors associated with increased 28-day mortality were the sequential organ failure assessment score at ICU admission ( P  < .001) and advance in age ( P = 0.03). The factors associated with increased hospital mortality were a high sequential organ failure assessment score at ICU admission ( P  < 0.01), advance in age ( P  = 0.04), and the presence of lymphoma-related HLH or HLH of unknown origin ( P  < 0.01). Organ failure overtops the classical early-death risk factors in adult ICU-admitted HLH patients. This failure and the subsequent early death may be prevented by timely specific cytotoxic therapies and the control of the underlying disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here